Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be m
more on seekingalpha.com
Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be m